KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Teva Pharmaceutical Industries (TEVA) Other Gross PP&E Adjustments (2016 - 2025)

Teva Pharmaceutical Industries' Other Gross PP&E Adjustments history spans 17 years, with the latest figure at $2.8 billion for Q4 2025.

  • For the quarter ending Q4 2025, Other Gross PP&E Adjustments fell 34.33% year-over-year to $2.8 billion, compared with a TTM value of $2.8 billion through Dec 2025, down 34.33%, and an annual FY2025 reading of $2.8 billion, down 34.33% over the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was $2.8 billion at Teva Pharmaceutical Industries, up from -$342.0 million in the prior quarter.
  • The five-year high for Other Gross PP&E Adjustments was $6.1 billion in Q4 2023, with the low at -$531.0 million in Q2 2021.
  • Average Other Gross PP&E Adjustments over 5 years is $799.0 million, with a median of -$364.0 million recorded in 2024.
  • Year-over-year, Other Gross PP&E Adjustments plummeted 585.14% in 2021 and then surged 97.65% in 2022.
  • Tracing TEVA's Other Gross PP&E Adjustments over 5 years: stood at $3.1 billion in 2021, then surged by 97.65% to $6.1 billion in 2022, then grew by 0.51% to $6.1 billion in 2023, then dropped by 29.84% to $4.3 billion in 2024, then tumbled by 34.33% to $2.8 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Other Gross PP&E Adjustments are $2.8 billion (Q4 2025), -$342.0 million (Q3 2025), and -$358.0 million (Q2 2025).